ArticleMedicine international
Post-operative liver metastasis from gastric cancer with HER2-positive areas newly identified upon re-evaluation, leading to a favorable response to trastuzumab-based therapy: A case report.
Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in molecular targeted agents and immune checkpoint inhibitors have markedly improved outcomes in patients with unresectable or recurrent advanced-stage gastric cancer. As treatment options continue to expand, biomarker testing has become essential for determining first-line treatment strategies. Among these, human epidermal growth factor receptor 2 (HER2) plays a key role in treatment selection; however, the intratumoral heterogeneity of HER2 expression in gastric cancer has long been recognized and may influence therapeutic decision-making. The present study describes the case of a patient who was initially diagnosed as having a HER2 score of 0 on the surgical specimen, but was later found to have a HER2 score of 2+ with FISH positivity upon reassessment, subsequently demonstrating a favorable response to trastuzumab-based therapy. The patient was a 79-year-old man with a type 3 lesion at the cardia, and enlarged lymph nodes adjacent to the primary tumor. The pre-operative diagnosis was cT4aN1M0, stage III. He underwent total gastrectomy. At 27 months post-surgery, MRI revealed a 21-mm metastatic lesion in liver segment 8. Given the initial HER2 score of 0, nivolumab plus the oxaliplatin + leucovorin + 5-fluorouracil regimen (mFOLFOX6) was initiated as first-line systemic therapy. However, as tumor markers continued to increase after two cycles, HER2 was re-evaluated using a different section from the resected specimen, which revealed a score of 2+ with FISH positivity. Therefore, the treatment was switched to trastuzumab plus mFOLFOX6. Following the regimen change, tumor markers decreased, and a CT scan demonstrated the shrinkage of the liver metastasis to 13 mm. Chemotherapy remains ongoing 7 months following the initiation trastuzumab treatment. On the whole, the present case report suggests that the reassessment of HER2 status may help identify patients who may benefit from HER2-targeted therapy, and may ultimately improve the therapeutic efficacy of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.